{
    "clinical_study": {
        "@rank": "100724", 
        "arm_group": [
            {
                "arm_group_label": "Artesunate-amodiaquine", 
                "arm_group_type": "Other", 
                "description": "Efficacy estimates at 95%"
            }, 
            {
                "arm_group_label": "Dihydroartemisinin-piperaquine", 
                "arm_group_type": "Other", 
                "description": "Efficacy estimates at 95%"
            }, 
            {
                "arm_group_label": "Artemether-lumefantrine", 
                "arm_group_type": "Other", 
                "description": "Efficacy estimates at 95%"
            }
        ], 
        "brief_summary": {
            "textblock": "Study treatments:\n\n        -  Artemether-lumefantrine\n\n        -  Artesunate-amodiaquine\n\n        -  Dihydroartemisinin-piperaquine\n\n      Location:\n\n      Maradi, Niger\n\n      Principal Objective:\n\n      To measure the clinical and parasitological efficacy of the three artemisinin combination\n      therapies over a period of 42 days from the start of treatment and with polymerase chain\n      reaction assay (PCR) adjustment.\n\n      Secondary objectives:\n\n        -  To determine the blood concentration of the non-artemisinin component of the treatment\n           (lumefantrine, desethylamodiaquine or piperaquine) at day 7\n\n        -  To assess the incidence of adverse events during the follow-up period;\n\n        -  To measure speed of parasite clearance\n\n      Methods:\n\n      In vivo non comparative study as for WHO standardised protocol. The study also measure the\n      concentration of the non-artemisinin component.\n\n      Target population:\n\n      Children under 5 years of age consulting the integrated health centres of Andoum\u00e9 and\n      Dix-sept portes in Maradi.\n\n      Sample size:\n\n      221 patients per study treatment; 663 patients in total.\n\n      Treatment allocation:\n\n      Random.\n\n      Outcomes:\n\n        -  Early treatment failure,\n\n        -  Late clinical failure,\n\n        -  Late parasitological failure,\n\n        -  Adequate clinical and parasitological response.\n\n      Analysis:\n\n        -  Cumulative success or failure rate (Kaplan-Meier analysis).\n\n        -  Proportions of early treatment failures, late clinical failures, late parasitological\n           failures, and adequate clinical and parasitological response (called also Per-protocol\n           analysis)."
        }, 
        "brief_title": "Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": [
                "Malaria", 
                "Malaria, Falciparum"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 6 and 59 months\n\n          -  Weight \u2265 5 kg\n\n          -  Mono-infection with P. falciparum detected by microscopy\n\n          -  Parasitic density between 2,000 and 200,000 asexual forms /\u00b5L of blood\n\n          -  Axillary temperature \u2265 37.5\u00b0C or history of fever during the previous 24 hours\n\n          -  Ability and willingness to comply with the protocol for the duration of the study and\n             to comply with the study visit schedule (home is within one hour of walk from the\n             outpatient department, no near-term travel plans, etc.)\n\n          -  Consent of a parent or guardian who is at least 18 years of age.\n\n        Exclusion Criteria:\n\n          -  Presence of general danger signs as defined by the WHO,\n\n          -  Presence of signs of severe malaria according to the definitions of WHO,\n\n          -  Severe anemia (haemoglobin <5 g/dL),\n\n          -  Known history of symptomatic cardiac arrhythmias or with clinically relevant\n             bradycardia,\n\n          -  Family history of sudden death or of congenital prolongation of corrected QT\n             interval,\n\n          -  Use of antiarrhythmics or neuroleptics,\n\n          -  Known history of hypersensitivity to any of the study medications,\n\n          -  Severe malnutrition (defined as a weight-height ratio of < -3 z-score according to\n             the 2006 WHO reference (20) and / or a mid-upper arm circumference lower than 115 mm\n             and / or the presence of symmetrical oedema of the feet),\n\n          -  Presence of a febrile condition due to a disease other than malaria (i.e. measles,\n             acute lower respiratory tract infection, otitis media, tonsillitis, abscess, severe\n             diarrhoea with dehydration, etc.)\n\n          -  History of a full treatment course with one of the three study drugs in the past 28\n             days. The prior incomplete intake of one of the three study drugs or prior intake of\n             antimalarial drugs not being tested in the study does not exclude a patient from\n             participating in this study. However, information on these previous treatments will\n             be carefully recorded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Months", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "663", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755559", 
            "org_study_id": "Epicentre/Nig/2012/Palu3ACT"
        }, 
        "intervention": [
            {
                "arm_group_label": "Artesunate-amodiaquine", 
                "description": "antimalarial ACT", 
                "intervention_name": "Artesunate-amodiaquine", 
                "intervention_type": "Drug", 
                "other_name": "AS-AQ Winthrop\u00ae Sanofi Aventis"
            }, 
            {
                "arm_group_label": "Dihydroartemisinin-piperaquine", 
                "description": "antimalarial ACT", 
                "intervention_name": "Dihydroartemisinin-piperaquine", 
                "intervention_type": "Drug", 
                "other_name": "Euratesim, Sigma-Tau"
            }, 
            {
                "arm_group_label": "Artemether-lumefantrine", 
                "description": "antimalarial ACT", 
                "intervention_name": "Artemether-lumefantrine", 
                "intervention_type": "Drug", 
                "other_name": "Coartem, Novartis"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amodiaquine", 
                "Artemether", 
                "Artemisinins", 
                "Artesunate", 
                "Dihydroquinghaosu", 
                "Piperaquine", 
                "Lumefantrine", 
                "Artemether-lumefantrine combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "malaria", 
            "artemisinin", 
            "artemisinin-based combination therapies", 
            "Plasmodium falciparum", 
            "efficacy"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "ousmane.GUINDO@epicentre.msf.org", 
                "last_name": "Ousmane Guindo, MD", 
                "phone": "+227 99 44 37 21"
            }, 
            "facility": {
                "address": {
                    "city": "Maradi", 
                    "country": "Niger"
                }, 
                "name": "Andoum\u00e9 Health Centre"
            }, 
            "investigator": {
                "last_name": "Ousmane Guindo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Niger"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13", 
        "overall_contact": {
            "email": "francesco.GRANDESSO@epicentre.msf.org", 
            "last_name": "Francesco Grandesso, MSc", 
            "phone": "+33 1 40 21 54 63"
        }, 
        "overall_contact_backup": {
            "email": "jean-francois.etard@epicentre.msf.org", 
            "last_name": "Jean-Fran\u00e7ois Etard, PhD", 
            "phone": "+33 1 40 21 54 82"
        }, 
        "overall_official": [
            {
                "affiliation": "Epicentre", 
                "last_name": "Francesco Grandesso, MSc", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Epicentre", 
                "last_name": "Lynda Woi Messe, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Cermes", 
                "last_name": "Ibrahim M Laminou, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Epicentre", 
                "last_name": "Jean-Fran\u00e7ois Etard, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Niger: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Absence of parasitaemia on day 42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.", 
            "measure": "Adequate clinical and parasitological response", 
            "safety_issue": "No", 
            "time_frame": "42 days after treatement start"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755559"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "General danger signs or signs of severe malaria on days 1, 2, or 3, in the presence of parasitaemia , or\nParasitaemia on day 2 higher than on day 0, irrespective of axillary temperature, or\nParasitaemia on day 3 with axillary temperature \u2265 37.5\u00b0C, or\nParasitaemia on day 3 \u2265 25% count on day 0 irrespective of axillary temperature.", 
                "measure": "Early treatment failure", 
                "safety_issue": "No", 
                "time_frame": "1 to 3 days after tratment start"
            }, 
            {
                "description": "General danger signs or severe malaria in the presence of parasitaemia on any day between day 4 and day 42 in patients who did not previously meet any of the criteria of early treatment failure; or\nPresence of parasitaemia on any day between day 4 and day 42 with axillary temperature \u2265 37.5 \u00b0C in patients who did not previously meet any of the criteria of early treatment failure.", 
                "measure": "Late clinical failure", 
                "safety_issue": "No", 
                "time_frame": "from day 4 to day 42 after treatment start"
            }, 
            {
                "description": "- Presence of parasitaemia on any day between day 7 and day 42 with axillary temperature < 37.5 \u00b0C in patients who did not previously meet any of the criteria of early treatment failure or late clinical failure.", 
                "measure": "Late Parasitological Failure", 
                "safety_issue": "No", 
                "time_frame": "from day 7 to day 42 after treatment start"
            }
        ], 
        "source": "Epicentre", 
        "sponsors": {
            "collaborator": {
                "agency": "Centre de Recherche M\u00e9dicale et Sanitaire (Cermes), Niamey", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Epicentre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}